Sartorius Stedim Biotech SA

DIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|^kLOCK|ldLOCK|K%$%&F!

Sartorius Stedim Earnings: Guidance Confirmed, Equipment Recovery Awaited; Shares Undervalued

Sartorius Stedim reported first-quarter constant-currency sales growth of 7.9%, with both segments contributing healthy numbers. Underlying EBITDA margin declined 10 basis points to 30.7%. Management confirmed its full-year guidance.

Sponsor Center